This application is a continuation of Bishop et al., U.S. Patent Application Publ. No. 2018/0256351, published Sep. 13, 2018, and entitled “Implant with Structural Members Arranged Around a Ring,” the entire disclosure of which is hereby incorporated by reference.
The embodiments are generally directed to implants for supporting bone growth in a patient.
A variety of different implants are used in the body. Implants used in the body to stabilize an area and promote bone ingrowth provide both stability (i.e. minimal deformation under pressure over time) and space for bone ingrowth.
Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical treatment method used for the treatment of various morbidities such as degenerative disc disease, spondylolisthesis (slippage of a vertebra), spinal stenosis, scoliosis, fracture, infection or tumor. The aim of the spinal fusion procedure is to reduce instability and thus pain.
In preparation for the spinal fusion, most of the intervertebral disc is removed. An implant, the spinal fusion cage, may be placed between the vertebra to maintain spine alignment and disc height. The fusion, i.e. bone bridge, occurs between the endplates of the vertebrae.
In one aspect, an implant includes a body including a ring with an opening. The body defines a transverse plane dividing the implant into a superior half and an inferior half. The ring defines a radial direction and a circumferential direction. The implant includes a bone contacting member attached to the ring, where the bone contacting member extends radially from the ring. The implant also includes a support member attached to the bone contacting member at an attachment region, where the support member extends in the circumferential direction.
In another aspect, an implant includes a body. The body defines a transverse plane dividing the implant into a superior half and an inferior half. The implant includes a first bone contacting member attached to the body and disposed within the superior half of the implant. The implant also includes a first support member attached to the first bone contacting member, the first support member being disposed within the superior half of the implant. The implant also includes a second bone contacting member attached to the body and disposed within the inferior half of the implant. The implant also includes a second support member attached to the second bone contacting member, the second support member being disposed within the inferior half of the implant. An end of the first support member is attached to an end of the second support member.
In another aspect, an implant includes a body and a plurality of bone contacting members extending from a central region of the body to a periphery of the body. Each of the bone contacting members in the plurality of bone contacting members extend radially away from the central region of the body.
Other systems, methods, features and advantages of the embodiments will be, or will become, apparent to one of ordinary skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description and this summary, be within the scope of the embodiments, and be protected by the following claims.
The embodiments can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, with emphasis instead being placed upon illustrating the principles of the embodiments. Moreover, in the figures, like reference numerals designate corresponding parts throughout the different views.
The embodiments described herein are directed to an implant for use in a spine. The embodiments include implants with a body and one or more structural members. In addition to the various provisions discussed below, any embodiments may make use of any of the body/support structures, frames, plates, coils or other structures disclosed in Morris et al., U.S. Pat. No. 9,918,849, issued on Mar. 20, 2018, and titled “Coiled Implants and Systems and Methods of Use Thereof,” which is hereby incorporated by reference in its entirety. For purposes of convenience, the Morris application will be referred to throughout the application as “The Coiled Implant Application”. Also, any embodiments may make use of any of the body/support structures, elements, frames, plates or other structures disclosed in McShane III et al., U.S. Publication Number 2019/0000642, published on Jan. 3, 2019, and titled “Implant with Arched Bone Contacting Elements,” which is hereby incorporated by reference in its entirety. Also, any embodiments may make use of any of the body/support structures, elements, frames, plates or other structures disclosed in McShane III et al., U.S. Publication Number 2018/0110626, published on Apr. 26, 2018, and titled “Implant with Protected Fusion Zones,” which is hereby incorporated by reference in its entirety and referred to as “The Protective Fusion Zones application”.
In some embodiments, implant 100 may include a body 102. Body 102 may generally provide a frame or skeleton for implant 100. In some embodiments, implant 100 may also include a plurality of structural members 104. Plurality of structural members 104 may be fixedly attached to, and/or continuously formed (or “integrally formed”) with, body 102. As used herein, the term “fixedly attached” shall refer to two components joined in a manner such that the components may not be readily separated (for example, without destroying one or both components).
As used herein, each structural member comprises a distinctive member or element that spans a portion of an implant. Structural members may overlap or intersect, similar to elements in a lattice or other 3D mesh structure. Some embodiments may use structural members in which the length of the member is greater than its width and its thickness. In embodiments where a structural member has an approximately circular cross-sectional shape, the structural member has a length greater than its diameter. In the embodiments seen in
For purposes of clarity, reference is made to various directional adjectives throughout the detailed description and in the claims. As used herein, the term “anterior” refers to a side or portion of an implant that is intended to be oriented towards the front of the human body when the implant has been placed in the body. Likewise, the term “posterior” refers to a side or portion of an implant that is intended to be oriented towards the back of the human body following implantation. In addition, the term “superior” refers to a side or portion of an implant that is intended to be oriented towards a top (e.g., the head) of the body while “inferior” refers to a side or portion of an implant that is intended to be oriented towards a bottom of the body. Reference is also made herein to “lateral” sides or portions of an implant, which are sides, or portions, facing along a lateral direction of the body (which correspond with the left or right sides of a patient).
In
Reference is also made to directions or axes that are relative to the implant itself, rather than to its intended orientation with regards to the body. For example, the term “distal” refers to a part that is located further from a center of an implant, while the term “proximal” refers to a part that is located closer to the center of the implant. As used herein, the “center of the implant” could be the center of mass and/or a central plane and/or another centrally located reference surface.
An implant may also be associated with various axes. Referring to
An implant may also be associated with various reference planes or surfaces. As used herein, the term “median plane” refers to a vertical plane which passes from the anterior side to the posterior side of the implant, dividing the implant into right and left halves, or lateral halves. As used herein, the term “transverse plane” refers to a horizontal plane located in the center of the implant that divides the implant into superior and inferior halves. As used herein, the term “coronal plane” refers to a vertical plane located in the center of the implant that divides the implant into anterior and posterior halves. In some embodiments, the implant is symmetric about two planes, such as the median and the transverse plane.
In some embodiments, one or more sides of an implant (including lateral sides and/or anterior/posterior sides) could include a vertically oriented peripheral frame portion. In the embodiment of
Although the present embodiment uses a vertically oriented frame or wall on the anterior side of implant 100, in other embodiments, a vertically oriented frame or wall could be located on the posterior side of implant 100 and/or on a lateral side of implant 100. In still other embodiments, the implant may lack any vertical walls along its perimeter (i.e., along the posterior, anterior or lateral sides).
Embodiments may include one or more rings. In some embodiments, an implant could include two or more rings that are connected in a ring assembly. As seen in
As seen in
In different embodiments, the location of a ring assembly could vary. For purposes of characterizing possible locations of a ring assembly, an implant may be divided into a first lateral side region, a second lateral side region and a central region disposed between the first lateral side region and the second lateral side region. In the exemplary embodiment of
It may be appreciated that in other embodiments a ring assembly could be disposed centrally with respect to a posterior/anterior direction. Though, in the present embodiment, ring assembly 220 extends the full distance between the posterior and anterior edges of implant 100.
In different embodiments, the shape of a ring could vary. In the exemplary embodiment, superior ring 222 and inferior ring 224 each have an oval-like shape. However, in other embodiments, a ring could have any other shape including, but not limited to, a rounded shape, a circular shape, a triangular shape, a square shape, a polygonal shape, a regular shape, an irregular shape, etc.
A ring assembly, including a superior ring and an inferior ring, could be attached to other portions of the implant in various ways. In some embodiments, a ring assembly may be attached directly to a peripheral frame portion of a body. In other embodiments, a ring assembly could be attached to the body by way of one or more structural members. In the exemplary embodiment, ring assembly 220 is attached directly to both peripheral frame portion 206 and vertically oriented peripheral frame portion 208, while also being attached to a plurality of structural members (see
Some embodiments can include provisions that facilitate implantation, including insertion and/or fixation of the implant. Some embodiments can include a fastener receiving portion. For example, as best seen in
In some embodiments, an implant can be configured with one or more symmetries. In some cases, an implant may have a mirrored symmetry about one or more reference planes.
Referring to
With respect to the transverse plane (which coincides generally with the plane defined by first lateral frame portion 202, second lateral frame portion 204 and posterior frame portion 206), it may be seen that the superior half of implant 100 mirrors the inferior half of implant 100, at least approximately. This includes not only the geometry of the body but also the shape, size and orientations of each structural member.
Moreover, with respect to the median plane (which approximately divides implant 100 into two lateral halves), it may be seen that two lateral halves mirror one another approximately. This includes not only the geometry of the body but also the shape, size and orientations of each structural member.
An implant may include two or more kinds of structural members (or structural elements). In some embodiments, an implant can include one or more bone contacting structural members, or simply “bone contacting members”. Bone contacting members may generally be fully exposed on the outer surfaces of an implant, including along the superior and inferior sides of the implant. Thus, bone contacting members may be alternatively referred to as “outer members”.
In some embodiments, an implant can include one or more structural members that provide support to one or more bone contacting members. Such supporting structural members may be referred to as “support members”. In some embodiments, at least some portions of each support member may be hidden or covered by a bone contacting member or another element of the implant. Thus, support members may also be characterized as “inner members” as they are generally disposed inwardly of the bone contacting members.
The following discussion discusses exemplary structural members in some, but not all, of the quadrants of implant 100. However, it may be appreciated that similar properties and principles of the specific structural members discussed here may apply to structural members in any of the remaining quadrants.
In some embodiments, one or more structural members could be closed loops without ends. In other embodiments, at least some structural member comprises two ends. In some cases, structural members with two ends could include one or more ends that are attached to another structural member. In other cases, structural members with two ends could be arranged so that both ends are attached to a portion of a body of an implant. In the exemplary embodiment depicted in
In some embodiments, an implant may include at least one bone contacting member with one end attached to a frame portion and another end attached to a central ring. For example, as seen in
In different embodiments, support members could be attached to different portions of an implant. In some embodiments, one or more ends of a support member could be attached to a peripheral frame portion of a body. In other embodiments, one or more ends could be attached to another support member. In still other embodiments, one or more portions of a support member could be attached to a bone contacting member. In one embodiment, each support member may be attached to a peripheral frame portion of the body, at least one bone contacting member, and at least one other support member.
In the exemplary embodiment of
Embodiments may include provisions to minimize the number of bars or other supports needed. Some embodiments may include provisions that eliminate the need for any internal supports extending between peripheral frame portion 200 (shown in
In some embodiments, bone contacting members may be disposed distal to support members, with bone contacting members generally disposed further outwards along the superior and inferior sides of an implant. Thus, bone contacting members may generally be disposed closer to the vertebral end plates following implantation into the spine. Moreover, at regions where a bone contacting member is attached to a support member, the attached portion of the bone contacting member may be disposed distal to the attached portion of the inner member. As one example,
Embodiments can include provisions for protecting bone growth along and adjacent to bone contacting members of an implant. In some embodiments, a bone contacting member can be configured with a geometry that helps to protect new bone growth in selected regions or “protected fusion zones”. In some embodiments, a bone contacting member can have a spiral, helical or twisted geometry that provide a series of such protected fusion zones for enhanced bone growth.
Some bone contacting members may have a generalized helical geometry. As used herein, a “generalized helical geometry” or “spiraling geometry” refers to a geometry where a part (portion, member, etc.) winds, turns, twists, rotates or is otherwise curved around a fixed path. In some cases, the fixed path could be straight. In other cases, the fixed path can be curved. In the present embodiments, for example, the fixed path is generally a combination of straight segments and curved segments.
Curves having a generalized helical geometry (also referred to as generalized helical curves) may be characterized by “coils”, “turns” or “windings” about a fixed path. Exemplary parameters that may characterize the specific geometry of a generalized helical curve can include coil diameter (including both a major and minor diameter) and the pitch (i.e., spacing between adjacent coils). In some cases, the “amplitude” of a coil or loop may also be used to describe the diameter or widthwise dimension of the coil or loop. Each of these parameters could be constant or could vary over the length of a generalized helical curve.
Generalized helical curves need not be circular or even round. In some embodiments, for example, a generalized helical curve could have linearly segmented shape (or locally polygonal shape) such that each “coil” or “turn” is comprised of straight line segments rather than arcs or other curved segments. Generalized helical curves may also include combinations of curved and straight segments. Examples of generalized helical curves are shown and described in The Protected Fusion Zones Application.
For purposes of characterizing the geometry of one or more structural members, each structural member can be understood to have a “central member curve”. The central member curve of each structural member may be defined as a curve that extends along the length of the structural member such that each point along the curve is centrally positioned within the structural member.
In embodiments where a structural member winds or loops around a fixed path with an amplitude or diameter that is much greater than the cross-sectional diameter of the structural member itself, the structural member may be wound into visible distinct coils. Such coils are discussed in thorough detail in the Coiled Implant Application. In other embodiments, however, a structural member could be wound around a fixed path with an amplitude or diameter that is less than the cross-sectional diameter of the structural member itself. In such a case the resulting geometry of a structural member may appear to be twisted, but the geometry may lack the distinct coils seen in the Coiled Implant Application. However, it may be appreciated that while the outermost surface of such a structural member may not exhibit distinct coils, the central member curve of the structural member does have such coils or turns and moreover has a clear generalized helical geometry.
As previously discussed, bone contacting member 300 (
In different embodiments, the winding diameter of a helical structural member could vary. In the exemplary embodiment, a winding diameter 552 of the coils or turns in central member curve 520 are smaller than the diameter of bone contacting member 300. In other embodiments, the cross-sectional diameter of a bone contacting member could be less than a corresponding winding diameter of the coils or turns of its central member curve. In such an embodiment, the bone contacting member would be configured in a series of distinct coils.
A bone contacting member may not have a generalized helical geometry through its entire length. Instead, its central member curve may be configured with a winding segment where the central member curve completes several full turns (three in
Although the present embodiment includes at least one bone contacting member with a winding segment that makes one or more full turns around a fixed path, other embodiments could be configured with central member curves that only make partial turns around a fixed path.
While the description here has focused on the geometry of a single bone contacting member 300, it may be appreciated that some or all of the remaining bone contacting members in plurality of structural members 104 may have a similar generalized helical geometry. It may be further appreciated that two different bone contacting members could have slightly different geometries, with distinct bone contacting member curves that include variations in the number of windings, shape of the windings, etc.
In some embodiments, an implant can include bone contacting members that are locally helical over small distances compared to the length, width or height of the implant. For example, implant 100 may be characterized as having bone contacting members that are locally helical or locally spiraling, rather than globally helical. In particular, each bone contacting member of implant 100 is bounded within a single quadrant of implant 100 and does not cross the transverse plane or the median plane of implant 100. Thus, a full turn of the bone contacting members is accomplished over distances that are much smaller than half the length, width or height of the implant. This allows multiple windings within each quadrant of the implant and also results in the pitch between windings being smaller than the length, width or height of the implant. For example, in
In some embodiments, the helix-like geometry of bone contacting members provides distinct regions exposed on the superior and inferior sides of an implant. For example, referring to
Bone contacting members may also include proximal regions 362 that are configured as “valleys” in the bone contacting member along the superior side 130 of implant 100. Whereas the distal regions 360 may come into contact with the vertebrae during and following implantation of implant 100, proximal regions 362 may be recessed or spaced apart from direct contact with the vertebrae, at least before new bone growth has developed.
As a particular example,
While bone contacting members may have generalized helical geometries, the geometries of the support members may be selected to enhance strength and support. In some embodiments, support members could have a generally tube-like (solid) shape and may extend in simple curves from one portion of a body to another. In some cases, the central member curve of a support member may be smoothly curved without any local twists, windings or coils.
Thus, it may be appreciated, that in some embodiments, support members may generally be shorter and their geometry may be more arch-like to improve strength and provide increased support for the bone contacting members. In contrast, the bone contacting members may generally have a longer length and may be less arch-like in shape relative to the support members, as the bone contacting members need to extend across as much of the superior/inferior sides of an implant as possible to provide contact with the vertebrae.
While some embodiments include bone contacting members with generalized helical geometries and support members with arch-like geometries, in other embodiments any structural member could be configured with any type of geometry. For example, in another embodiment, one or more support members could have a generalized helical geometry that create protected fusion zones along the support members. In still another embodiment, one or more bone contacting members could have an arch-like geometry.
In different embodiments, the attachment between a support member and a bone contacting member could occur at various locations. In some embodiments, a support member could be attached near a distal surface region along the outer surface of a bone contacting member. In other embodiments, a support member could be attached near a proximal surface region along the outer surface of a bone contacting member.
In some embodiments, each support member is configured to attach to a corresponding bone contacting member at a location adjacent (or underlying) a proximal surface region of the bone contacting member. For example, as shown in
This configuration provides for protected fusion zones that encompass the space immediately adjacent the proximal regions. The protected fusion zones are locations along the superior/inferior surfaces of an implant where new bone growth can be partially protected from forces applied to the bone contacting members by adjacent support members or directly from a vertebra.
By configuring one or more bone contacting members with at least one helical portion, the bone contacting member may provide one or more protected fusion zones on the superior and inferior sides of an implant. These protected fusion zones encompass the space immediately adjacent the proximal regions of the bone contacting members. The recessed spaces provided by the proximal regions allow for pockets of new bone growth adjacent initial fusion that may occur at the distal regions. Moreover, because the support members are attached near the proximal surface regions, and not at the distal surface regions, forces applied to the bone contacting members by either the support members or by a vertebra can be directed away from the protected fusion zones, thereby minimizing the disturbance of new bone growth.
For purposes of reference, central opening 650 (and ring 609) define a radial direction 599 and a circumferential direction 598. Here, radial direction 599 extends outwardly from a center of central opening 650, while circumferential direction 598 is an angular direction that is perpendicular with radial direction 599.
In different embodiments, the orientation of bone contacting members and/or support members could vary. In some embodiments, bone contacting members may be oriented radially away from a center of an implant. In some embodiments, support members may be oriented in a circumferential (or angular) direction that rotates about a center of an implant. In other embodiments, however, bone contacting members could be oriented in a circumferential direction while support members could be oriented in a radial direction. In still other embodiments, one or more structural elements could be oriented in directions orthogonal to the length and/or width of an implant, rather than in radial and/or circumferential directions.
Implant 600 also includes plurality of bone contacting members 630 and plurality of support members 632. As seen in
As seen in
The embodiment of
This web-like pattern provides radially oriented structural members (bone contacting members) that may help improve strength in multiple directions simultaneously (i.e., the longitudinal and lateral directions). This may also help direct new bone growth from the center of the device (which includes a large central cavity for bone growth) towards the corners and periphery of the device. Moreover, the circumferential orientation of some structural members (support members) in this web-like pattern also improves the strength of the device in multiple directions simultaneously and in directions orthogonal to the radially oriented structural members.
The arrangement of structural members with the body may also be designed to achieve a desired total open volume. As used herein a total volume is the combined volume of any openings between structural members, any openings in the body, or between structural members and the body. This open configuration may facilitate bone growth in and through the implant. A portion, or substantially all of, the open spaces is optionally filled with a bone graft or bone growth promoting material prior to or after insertion of the implant to facilitate bone growth.
The total volume of the open spaces (also referred to simply as the open space volume) within any particular implant is dependent on the overall dimension of the implant as well as the size and dimension of individual components within the implant including structural members, frame portions, etc. The open space volume may range from about 20% to 80% of the volume of the implant. In some embodiments, implant 100 may have an open space volume that is between 25% and 80% of the implant's total volume. In still further embodiments, implant 100 may have an open space volume that is between 40% and 75% of the total implant volume.
Some bone growth promoting materials may also be applied to an implantable prosthesis through the use of a plasma spray or electrochemical techniques. Examples of these materials include, but are not limited to, hydroxyapatite, beta tri-calcium phosphate, calcium sulfate, calcium carbonate, as well as other chemicals.
A bone growth promoting material can include, or may be used in combination with, a bone graft or a bone graft substitute. A variety of materials may serve as bone grafts or bone graft substitutes, including autografts (harvested from the iliac crest of the patient's body), allografts, demineralized bone matrix, and various synthetic materials.
Some embodiments may use autograft. Autograft provides the spinal fusion with calcium collagen scaffolding for the new bone to grow on (osteoconduction). Additionally, autograft contains bone-growing cells, mesenchymal stem cells and osteoblast that regenerate bone. Lastly, autograft contains bone-growing proteins, including bone morphogenic proteins (BMPs), to foster new bone growth in the patient.
Bone graft substitutes may comprise synthetic materials including calcium phosphates or hydroxyapatites, stem cell containing products which combine stem cells with one of the other classes of bone graft substitutes, and growth factor containing matrices such as INFUSE® (rhBMP-2-containing bone graft) from Medtronic, Inc.
It should be understood that the provisions listed here are not meant to be an exhaustive list of possible bone growth promoting materials, bone grafts or bone graft substitutes.
In some embodiments, BGPM may be applied to one or more outer surfaces of an implant. In other embodiments, BGPM may be applied to internal volumes within an implant. In still other embodiments, BGPM may be applied to both external surfaces and internally within an implant. As seen in
In different embodiments, implantation methods could vary. In some embodiments, implant 600 may be secured to an implantation tool 701 (partially seen in
Initial bone fusion and growth may occur where the vertebrae are in contact with BGPM 700. With time, new bone growth begins to extend along the inferior and superior surfaces of implant 600 as well as into central cavity 671, as seen in
Eventually, as seen in
In
As shown in
It may be appreciated that new bone growth similarly occurs on the inferior surface of implant 600, as well as extending around the lateral, posterior and anterior sides.
Finally, as seen in
In some other embodiments, increased volume for bone graft material and eventually new bone growth may be created by removing one or more structures that are disposed within an internal region of an implant. For example, in another embodiment, the structures connecting superior and inferior rings (e.g., first support 226 and second support 228 shown in
Embodiments can include provisions for texturing one or more surfaces of an implant. Such texturing can increase or otherwise promote bone growth and/or fusion to surfaces of the implant. In some embodiments, bone contacting members may be textured while support members may not be textured. This helps initial bone growth to be directed along the bone contacting members and especially into the protected fusion zones, rather than growing initially across support members. In other embodiments, however, support members could include surface texturing. In still further embodiments, one or more surfaces of a body could include surface texturing.
In some embodiments, the surface structure of one or more regions of an implant may be roughened or provided with irregularities. Generally, this roughened structure may be accomplished through the use of acid etching, bead or grit blasting, sputter coating with titanium, sintering beads of titanium or cobalt chrome onto the implant surface, as well as other methods. In some embodiments, the roughness can be created by 3D printing a raised pattern on the surface of one or more regions of an implant. In some embodiments, the resulting roughened surface may have pores of varying sizes. In some embodiments, pore sizes could range between approximately 0.2 mm and 0.8 mm. In one embodiment, pore sizes could be approximately 0.5 mm. In other embodiments, surface roughness comprising pore sizes less than 0.2 mm and/or greater than 0.8 mm are possible.
The embodiments can make use of the surface texturing parts, features, processes or methods as disclosed in The Protected Fusion Zone Application.
The implants for use in the spine have overall dimensions suitable for insertion in the spine, typically between two vertebral bodies. The shape of the implant and dimensions depends on the site into which it is inserted. Exemplary heights for implants such as implant 100 and implant 600 include, but are not limited to, 5 mm to 30 mm. Other embodiments could have incremental heights of any value in the range between the aforementioned range, most often between 8 mm and 16 mm. Still other embodiments could have a height greater than 16 mm. Still other embodiments could have a height less than 8 mm. Additionally, the horizontal footprint of the implant could vary. Exemplary footprint sizes for any embodiments of the implant include, but are not limited to, 15-20 mm in the anterior-posterior direction and 40-60 mm in the lateral-lateral direction. Still other embodiments could be configured with any other footprint sizes.
The dimensions of one or more structural members could vary. In some embodiments, a structural member could have a cross-sectional diameter in a range between 0.2 and 3 mm. For structural members with polygonal cross sections, the dimensions characterizing the polygon (e.g., first and second diameters for an ellipse) could vary. As an example, a structural member with an elliptic cross section could have a cross section with a first diameter in a range between 0.2 mm and 3 mm and a second diameter in range between 0.2 mm and 3 mm. In other embodiments, a structural member could have any other cross-sectional diameter. Moreover, in some cases a bone contacting member and a support member could have similar cross-sectional diameters while in other cases a bone contacting member and a support member could have different cross-sectional diameters.
Embodiments can also be provided with various flat/parallel (0-degree), lordotic, and hyper-lordotic angles. In some embodiments, the implant can be configured with an approximately 8-degree angle between the superior and inferior surfaces. In other embodiments, the implant can be configured with an approximately 15-degree angle between the superior and inferior surfaces. In still other embodiments, the implant can be configured with an approximately 20-degree angle between the superior and inferior surfaces. Still other angles are possibly including any angles in the range between 0 and 30 degrees. Still other embodiments can provide a lordotic angle of less than 8 degrees. Still other embodiments can provide a hyper-lordotic angle of more than 20 degrees. In at least some embodiments, the lordotic angle of the implant is accomplished via the geometry of the central keel portion and the side frame portion (posterior or anterior).
The various components of an implant may be fabricated from biocompatible materials suitable for implantation in a human body, including but not limited to, metals (e.g. titanium or other metals), synthetic polymers, ceramics, and/or their combinations, depending on the particular application and/or preference of a medical practitioner.
Generally, the implant can be formed from any suitable biocompatible, non-degradable material with sufficient strength. Typical materials include, but are not limited to, titanium, biocompatible titanium alloys (e.g. γTitanium Aluminides, Ti6—Al4—V ELI (ASTM F 136 and F 3001), or Ti6—Al4—V (ASTM F 2989, F 1108 and ASTM F 1472)) and inert, biocompatible polymers, such as polyether ether ketone (PEEK) (e.g. PEEK-OPTIMA®, Invibio Inc and Zeniva Solvay Inc.). Optionally, the implant contains a radiopaque marker to facilitate visualization during imaging.
In different embodiments, processes for making an implant can vary. In some embodiments, the entire implant may be manufactured and assembled via readditional/CNC machining, injection-molding, casting, insert-molding, co-extrusion, pultrusion, transfer molding, overmolding, compression molding, 3-Dimensional (3-D) printing (including Direct Metal Laser Sintering and Electron Beam Melting), dip-coating, spray-coating, powder-coating, porous-coating, milling from a solid stock material and their combinations. Moreover, the embodiments can make use of any of the features, parts, assemblies, processes and/or methods disclosed in the “The Coiled Implant Application”.
While various embodiments have been described, the description is intended to be exemplary, rather than limiting, and it will be apparent to those of ordinary skill in the art that many more embodiments and implementations are possible that are within the scope of the embodiments. Although many possible combinations of features are shown in the accompanying figures and discussed in this detailed description, many other combinations of the disclosed features are possible. Any feature of any embodiment may be used in combination with or substituted for any other feature or element in any other embodiment unless specifically restricted. Therefore, it will be understood that any of the features shown and/or discussed in the present disclosure may be implemented together in any suitable combination. Accordingly, the embodiments are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.
Number | Name | Date | Kind |
---|---|---|---|
4917704 | Frey et al. | Apr 1990 | A |
4961740 | Ray et al. | Oct 1990 | A |
5458638 | Kuslich et al. | Oct 1995 | A |
5571192 | Schonhoffer | Nov 1996 | A |
5607424 | Tropiano | Mar 1997 | A |
5609635 | Michelson | Mar 1997 | A |
5658337 | Kohrs et al. | Aug 1997 | A |
5709683 | Bagby | Jan 1998 | A |
5716416 | Lin | Feb 1998 | A |
5897556 | Drewry et al. | Apr 1999 | A |
6039762 | McKay | Mar 2000 | A |
6090143 | Meriwether et al. | Jul 2000 | A |
6126689 | Brett | Oct 2000 | A |
6149651 | Drewry et al. | Nov 2000 | A |
6200348 | Biedermann et al. | Mar 2001 | B1 |
6206924 | Timm | Mar 2001 | B1 |
6371987 | Weiland et al. | Apr 2002 | B1 |
6428575 | Koo et al. | Aug 2002 | B2 |
6436141 | Castro et al. | Aug 2002 | B2 |
6464727 | Sharkey | Oct 2002 | B1 |
6468309 | Lieberman | Oct 2002 | B1 |
6494883 | Ferree | Dec 2002 | B1 |
6500205 | Michelson | Dec 2002 | B1 |
6520996 | Manasas et al. | Feb 2003 | B1 |
6527805 | Studer et al. | Mar 2003 | B2 |
6537320 | Michelson | Mar 2003 | B1 |
6582467 | Teitelbaum et al. | Jun 2003 | B1 |
6585770 | White et al. | Jul 2003 | B1 |
6616695 | Crozet et al. | Sep 2003 | B1 |
6709458 | Michelson | Mar 2004 | B2 |
6758849 | Michelson | Jul 2004 | B1 |
6808537 | Michelson | Oct 2004 | B2 |
6846327 | Khandkar et al. | Jan 2005 | B2 |
6863689 | Ralph et al. | Mar 2005 | B2 |
6923810 | Michelson | Aug 2005 | B1 |
6962606 | Michelson | Nov 2005 | B2 |
6997953 | Chung et al. | Feb 2006 | B2 |
7135043 | Nakahara et al. | Nov 2006 | B2 |
7141068 | Ross et al. | Nov 2006 | B2 |
7153325 | Kim et al. | Dec 2006 | B2 |
7186267 | Aston et al. | Mar 2007 | B2 |
7241313 | Unwin et al. | Jul 2007 | B2 |
7341601 | Eisermann et al. | Mar 2008 | B2 |
7410501 | Michelson | Aug 2008 | B2 |
7429270 | Baumgartner et al. | Sep 2008 | B2 |
7435261 | Castro | Oct 2008 | B1 |
7452369 | Barry | Nov 2008 | B2 |
7465318 | Sennett et al. | Dec 2008 | B2 |
7485134 | Simonson | Feb 2009 | B2 |
7527649 | Blain | May 2009 | B1 |
7537616 | Branch et al. | May 2009 | B1 |
7621952 | Truckai et al. | Nov 2009 | B2 |
7621953 | Braddock, Jr. et al. | Nov 2009 | B2 |
7628814 | Studer et al. | Dec 2009 | B2 |
7655043 | Peterman et al. | Feb 2010 | B2 |
7794500 | Felix | Sep 2010 | B2 |
7799056 | Sankaran | Sep 2010 | B2 |
7803191 | Biedermann et al. | Sep 2010 | B2 |
7846207 | Lechmann et al. | Dec 2010 | B2 |
7875075 | Schwab | Jan 2011 | B2 |
7879100 | Denoziere et al. | Feb 2011 | B2 |
7879103 | Gertzman | Feb 2011 | B2 |
7935149 | Michelson | May 2011 | B2 |
8016887 | Castro | Sep 2011 | B1 |
8021424 | Beger et al. | Sep 2011 | B2 |
8021426 | Segal et al. | Sep 2011 | B2 |
8062365 | Schwab | Nov 2011 | B2 |
8092536 | Ahrens et al. | Jan 2012 | B2 |
8152849 | Biedermann et al. | Apr 2012 | B2 |
8182538 | O'Neil et al. | May 2012 | B2 |
8226718 | Castro | Jul 2012 | B2 |
8241363 | Sommerich et al. | Aug 2012 | B2 |
8246683 | Castro | Aug 2012 | B2 |
8252059 | Overes et al. | Aug 2012 | B2 |
8298286 | Trieu | Oct 2012 | B2 |
8303879 | Bertele et al. | Nov 2012 | B2 |
8328848 | Lowery et al. | Dec 2012 | B2 |
8361149 | Castro | Jan 2013 | B2 |
8366777 | Matthis et al. | Feb 2013 | B2 |
8414820 | Bertele et al. | Apr 2013 | B2 |
8430930 | Hunt | Apr 2013 | B2 |
8435300 | Messerli et al. | May 2013 | B2 |
8454700 | Lemoine et al. | Jun 2013 | B2 |
8475533 | Castro | Jul 2013 | B1 |
8551173 | Lechmann et al. | Oct 2013 | B2 |
8556978 | Schaller | Oct 2013 | B2 |
8613769 | Sears et al. | Dec 2013 | B2 |
8623090 | Butler | Jan 2014 | B2 |
8673006 | Castro | Mar 2014 | B2 |
8709042 | Greenhalgh et al. | Apr 2014 | B2 |
8740981 | Tornier et al. | Jun 2014 | B2 |
8771357 | Biedermann et al. | Jul 2014 | B2 |
8771368 | McKay | Jul 2014 | B2 |
8795362 | Anderson et al. | Aug 2014 | B2 |
8801787 | Schaller | Aug 2014 | B2 |
8808376 | Schaller | Aug 2014 | B2 |
8808725 | Altschuler et al. | Aug 2014 | B2 |
8864831 | Lee et al. | Oct 2014 | B2 |
8900312 | McLean et al. | Dec 2014 | B2 |
8932356 | Kraus | Jan 2015 | B2 |
8940052 | Lechmann et al. | Jan 2015 | B2 |
8951300 | Parrish | Feb 2015 | B2 |
8986383 | Castro | Mar 2015 | B2 |
9039766 | Fonte | May 2015 | B1 |
9173746 | Lowery et al. | Nov 2015 | B2 |
9186252 | Leibinger | Nov 2015 | B2 |
9186257 | Geisler et al. | Nov 2015 | B2 |
9247970 | Teisen | Feb 2016 | B2 |
9254199 | Biedermann et al. | Feb 2016 | B2 |
9271765 | Blain | Mar 2016 | B2 |
9271771 | Mathieu et al. | Mar 2016 | B2 |
9271845 | Hunt et al. | Mar 2016 | B2 |
9289308 | Marino et al. | Mar 2016 | B2 |
9295562 | Lechmann et al. | Mar 2016 | B2 |
9402733 | To et al. | Aug 2016 | B1 |
9408651 | Sennett et al. | Aug 2016 | B2 |
9421108 | Hunt | Aug 2016 | B2 |
9433510 | Lechmann et al. | Sep 2016 | B2 |
9433511 | Bagga et al. | Sep 2016 | B2 |
9439779 | Zhang et al. | Sep 2016 | B2 |
9439948 | Lin et al. | Sep 2016 | B2 |
9452064 | Trautwein et al. | Sep 2016 | B2 |
9456901 | Jones et al. | Oct 2016 | B2 |
9456907 | Castro | Oct 2016 | B1 |
9545317 | Hunt | Jan 2017 | B2 |
9549823 | Hunt et al. | Jan 2017 | B2 |
9561117 | Lechmann et al. | Feb 2017 | B2 |
9572669 | Hunt et al. | Feb 2017 | B2 |
9597197 | Lechmann et al. | Mar 2017 | B2 |
9622880 | Dunworth et al. | Apr 2017 | B2 |
9636226 | Hunt | May 2017 | B2 |
9649200 | Wickham | May 2017 | B2 |
9662224 | Weiman et al. | May 2017 | B2 |
9662226 | Wickham | May 2017 | B2 |
9744051 | Biedermann et al. | Aug 2017 | B2 |
9757235 | Hunt et al. | Sep 2017 | B2 |
9782270 | Wickham | Oct 2017 | B2 |
9788967 | Jo | Oct 2017 | B2 |
9814578 | Gotfried | Nov 2017 | B1 |
9907670 | DeRidder et al. | Mar 2018 | B2 |
9918849 | Morris | Mar 2018 | B2 |
9931209 | Gotfried | Apr 2018 | B2 |
9987051 | Nunley et al. | Jun 2018 | B2 |
9987137 | Hunt et al. | Jun 2018 | B2 |
9999516 | Hunt | Jun 2018 | B2 |
10004546 | Gotfried | Jun 2018 | B2 |
10016279 | Castro | Jul 2018 | B1 |
10058433 | Lechmann et al. | Aug 2018 | B2 |
10064737 | Tsai et al. | Sep 2018 | B2 |
10098754 | Larsson | Oct 2018 | B2 |
10117746 | Cordaro | Nov 2018 | B2 |
10143569 | Weiman et al. | Dec 2018 | B2 |
10154913 | Steinmann et al. | Dec 2018 | B2 |
10159580 | Guizzardi et al. | Dec 2018 | B2 |
10182923 | Willis et al. | Jan 2019 | B2 |
10194962 | Schneider et al. | Feb 2019 | B2 |
10195524 | DeRidder et al. | Feb 2019 | B2 |
10213317 | Bishop et al. | Feb 2019 | B2 |
10226357 | Ries | Mar 2019 | B2 |
10265189 | Melkent et al. | Apr 2019 | B2 |
10271958 | Schaufler et al. | Apr 2019 | B2 |
10278833 | Howard et al. | May 2019 | B2 |
10278834 | Howard et al. | May 2019 | B2 |
10357377 | Nyahay et al. | Jul 2019 | B2 |
10368997 | Jones et al. | Aug 2019 | B2 |
10369009 | Joly et al. | Aug 2019 | B2 |
10413427 | Trieu | Sep 2019 | B2 |
10433977 | Lechmann et al. | Oct 2019 | B2 |
10433979 | Morris et al. | Oct 2019 | B2 |
10449051 | Hamzey et al. | Oct 2019 | B2 |
10449055 | McJunkin | Oct 2019 | B2 |
10449058 | Lechmann et al. | Oct 2019 | B2 |
10478312 | McShane, III et al. | Nov 2019 | B2 |
10492921 | McShane, III et al. | Dec 2019 | B2 |
10507118 | Afzal | Dec 2019 | B2 |
10512549 | Bishop | Dec 2019 | B2 |
10517739 | Ryan | Dec 2019 | B2 |
10524926 | Jasinski | Jan 2020 | B2 |
10524927 | Ryan | Jan 2020 | B2 |
10524929 | Shoshtaev | Jan 2020 | B2 |
10525688 | O'Neill et al. | Jan 2020 | B2 |
10531962 | Petersheim et al. | Jan 2020 | B2 |
10537666 | Paddock et al. | Jan 2020 | B2 |
10555819 | Miccio | Feb 2020 | B2 |
10561456 | Cawley et al. | Feb 2020 | B2 |
10575965 | Kim et al. | Mar 2020 | B2 |
10588755 | Vogt et al. | Mar 2020 | B2 |
10617532 | Mazur et al. | Apr 2020 | B2 |
10624760 | Mirda et al. | Apr 2020 | B2 |
10660763 | Wilson et al. | May 2020 | B2 |
10660764 | Maglaras et al. | May 2020 | B2 |
10667924 | Nyahay et al. | Jun 2020 | B2 |
10675158 | Unger et al. | Jun 2020 | B2 |
10675385 | Barbas et al. | Jun 2020 | B2 |
10682238 | Petersheim et al. | Jun 2020 | B2 |
10695192 | Bishop et al. | Jun 2020 | B2 |
10709570 | Stauffer et al. | Jul 2020 | B2 |
10716678 | Stampfli et al. | Jul 2020 | B2 |
10722378 | Davis et al. | Jul 2020 | B2 |
10744001 | Sack | Aug 2020 | B2 |
10744003 | Ryan et al. | Aug 2020 | B2 |
10765530 | Steinmann et al. | Sep 2020 | B2 |
10772732 | Miller et al. | Sep 2020 | B1 |
10835388 | Milz et al. | Nov 2020 | B2 |
10849756 | Hunt et al. | Dec 2020 | B2 |
10856999 | Bishop et al. | Dec 2020 | B2 |
10940019 | Vishnubhotla et al. | Mar 2021 | B2 |
20010014826 | Biedermann et al. | Aug 2001 | A1 |
20010032018 | Castro et al. | Oct 2001 | A1 |
20020052656 | Michelson | May 2002 | A1 |
20020123750 | Eisermann et al. | Sep 2002 | A1 |
20030078660 | Clifford et al. | Apr 2003 | A1 |
20030083746 | Kuslich | May 2003 | A1 |
20040193270 | DiMauro et al. | Sep 2004 | A1 |
20040210312 | Neumann | Oct 2004 | A1 |
20040225361 | Glenn et al. | Nov 2004 | A1 |
20040243129 | Moumene | Dec 2004 | A1 |
20050177238 | Khandkar et al. | Aug 2005 | A1 |
20050187627 | Ralph | Aug 2005 | A1 |
20050222681 | Richley et al. | Oct 2005 | A1 |
20050278027 | Hyde, Jr. | Dec 2005 | A1 |
20060041262 | Calvert et al. | Feb 2006 | A1 |
20060052872 | Studer et al. | Mar 2006 | A1 |
20060052873 | Buck et al. | Mar 2006 | A1 |
20060058881 | Trieu | Mar 2006 | A1 |
20060100706 | Shadduck et al. | May 2006 | A1 |
20060147332 | Jones et al. | Jul 2006 | A1 |
20060293753 | Thramann | Dec 2006 | A1 |
20070027544 | McCord et al. | Feb 2007 | A1 |
20070179610 | Biedermann et al. | Aug 2007 | A1 |
20070198090 | Abdou | Aug 2007 | A1 |
20070260324 | Joshi et al. | Nov 2007 | A1 |
20080300602 | Schmitt et al. | Dec 2008 | A1 |
20080306595 | McLeod et al. | Dec 2008 | A1 |
20080312742 | Abernathie | Dec 2008 | A1 |
20090036985 | Whiting | Feb 2009 | A1 |
20090048678 | Saal et al. | Feb 2009 | A1 |
20090062917 | Foley et al. | Mar 2009 | A1 |
20090112321 | Kitchen | Apr 2009 | A1 |
20090149958 | Prewett et al. | Jun 2009 | A1 |
20090248162 | Peckham | Oct 2009 | A1 |
20100137990 | Apatsidis et al. | Jun 2010 | A1 |
20100286778 | Eisermann et al. | Nov 2010 | A1 |
20110015741 | Melkent et al. | Jan 2011 | A1 |
20110066192 | Frasier et al. | Mar 2011 | A1 |
20110166660 | Laurence | Jul 2011 | A1 |
20110190895 | Segal et al. | Aug 2011 | A1 |
20110245926 | Kitchen | Oct 2011 | A1 |
20110270401 | McKay | Nov 2011 | A1 |
20110301709 | Kraus et al. | Dec 2011 | A1 |
20110313532 | Hunt | Dec 2011 | A1 |
20120191188 | Huang | Jul 2012 | A1 |
20120191189 | Huang | Jul 2012 | A1 |
20120296431 | Kim et al. | Nov 2012 | A1 |
20130030529 | Hunt | Jan 2013 | A1 |
20130116793 | Kloss | May 2013 | A1 |
20130123935 | Hunt et al. | May 2013 | A1 |
20130158672 | Hunt | Jun 2013 | A1 |
20130184826 | Thaiyananthan | Jul 2013 | A1 |
20130190880 | Schaller | Jul 2013 | A1 |
20130204374 | Milella, Jr. | Aug 2013 | A1 |
20130218282 | Hunt | Aug 2013 | A1 |
20130218288 | Fonte et al. | Aug 2013 | A1 |
20130304211 | Trautwein et al. | Nov 2013 | A1 |
20130325129 | Huang | Dec 2013 | A1 |
20140058513 | Gahman et al. | Feb 2014 | A1 |
20140107786 | Geisler | Apr 2014 | A1 |
20140121776 | Hunt | May 2014 | A1 |
20140142707 | Compton et al. | May 2014 | A1 |
20140195005 | McKay | Jul 2014 | A1 |
20140243980 | Sack et al. | Aug 2014 | A1 |
20140277457 | Yeung et al. | Sep 2014 | A1 |
20140277464 | Richter et al. | Sep 2014 | A1 |
20140277569 | Lange | Sep 2014 | A1 |
20140288649 | Hunt | Sep 2014 | A1 |
20140288650 | Hunt | Sep 2014 | A1 |
20140303745 | Anderson et al. | Oct 2014 | A1 |
20140309743 | Falahee | Oct 2014 | A1 |
20140358246 | Levy et al. | Dec 2014 | A1 |
20150127106 | Partee | May 2015 | A1 |
20150282933 | Hunt | Oct 2015 | A1 |
20150282945 | Hunt | Oct 2015 | A1 |
20150282946 | Hunt | Oct 2015 | A1 |
20160045230 | Lowery et al. | Feb 2016 | A1 |
20160081809 | Schneider et al. | Mar 2016 | A1 |
20160193057 | Rhoda | Jul 2016 | A1 |
20160206439 | To et al. | Jul 2016 | A1 |
20160206440 | DeRidder et al. | Jul 2016 | A1 |
20160287388 | Hunt et al. | Oct 2016 | A1 |
20160324656 | Morris | Nov 2016 | A1 |
20170014235 | Jones et al. | Jan 2017 | A1 |
20170020685 | Geisler et al. | Jan 2017 | A1 |
20170042697 | McShane, III | Feb 2017 | A1 |
20170156879 | Janowski | Jun 2017 | A1 |
20170156880 | Halverson et al. | Jun 2017 | A1 |
20170216034 | Daniel | Aug 2017 | A1 |
20170216035 | Hunt | Aug 2017 | A1 |
20170239064 | Cordaro | Aug 2017 | A1 |
20170239066 | Walsh et al. | Aug 2017 | A1 |
20170258606 | Afzal | Sep 2017 | A1 |
20170319353 | Greenhalgh et al. | Nov 2017 | A1 |
20180064540 | Hunt et al. | Mar 2018 | A1 |
20180085230 | Hunt | Mar 2018 | A1 |
20180256336 | Mueller et al. | Sep 2018 | A1 |
20180256351 | Bishop | Sep 2018 | A1 |
20180256352 | Nyahay | Sep 2018 | A1 |
20180256353 | Nyahay | Sep 2018 | A1 |
20180296347 | Hamzey | Oct 2018 | A1 |
20180296350 | Hamzey et al. | Oct 2018 | A1 |
20180326493 | Gallagher et al. | Nov 2018 | A1 |
20180338838 | Cryder | Nov 2018 | A1 |
20180368981 | Mattes et al. | Dec 2018 | A1 |
20180368991 | Levieux | Dec 2018 | A1 |
20190015209 | Seifert et al. | Jan 2019 | A1 |
20190060083 | Weiman et al. | Feb 2019 | A1 |
20190076266 | Trudeau et al. | Mar 2019 | A1 |
20190083282 | Roeder et al. | Mar 2019 | A1 |
20190133769 | Tetsworth et al. | May 2019 | A1 |
20190151109 | Amin | May 2019 | A1 |
20190151113 | Sack | May 2019 | A1 |
20190159818 | Schneider et al. | May 2019 | A1 |
20190183653 | Gregersen et al. | Jun 2019 | A1 |
20190224023 | Howard et al. | Jul 2019 | A1 |
20190254840 | Gray et al. | Aug 2019 | A1 |
20190262139 | Wolters | Aug 2019 | A1 |
20190274841 | Hawkes et al. | Sep 2019 | A1 |
20190298542 | Kioss | Oct 2019 | A1 |
20190307574 | Nyahay et al. | Oct 2019 | A1 |
20190314169 | Patel et al. | Oct 2019 | A1 |
20190328546 | Palagi et al. | Oct 2019 | A1 |
20190336305 | Joly et al. | Nov 2019 | A1 |
20190343645 | Miccio et al. | Nov 2019 | A1 |
20190358058 | Trieu | Nov 2019 | A1 |
20190388238 | Lechmann et al. | Dec 2019 | A1 |
20200000603 | McJunkin | Jan 2020 | A1 |
20200036011 | Numata et al. | Jan 2020 | A1 |
20200038197 | Morris et al. | Feb 2020 | A1 |
20200038198 | Miccio | Feb 2020 | A1 |
20200086625 | O'Neill et al. | Mar 2020 | A1 |
20200113707 | Petersheim et al. | Apr 2020 | A1 |
20200113709 | Hsieh | Apr 2020 | A1 |
20200121470 | Moore et al. | Apr 2020 | A1 |
20200138595 | Shoshtaev et al. | May 2020 | A1 |
20200146842 | Jasinski | May 2020 | A1 |
20200155326 | Hunt | May 2020 | A1 |
20200179128 | Stalcup et al. | Jun 2020 | A1 |
20200179133 | Ryan | Jun 2020 | A1 |
20200188120 | Hamzey et al. | Jun 2020 | A1 |
20200188129 | McShane, III et al. | Jun 2020 | A1 |
20200188132 | Ryan | Jun 2020 | A1 |
20200188133 | McShane, III et al. | Jun 2020 | A1 |
20200190680 | Numata et al. | Jun 2020 | A1 |
20200197189 | Mazur et al. | Jun 2020 | A1 |
20200214852 | Tipping et al. | Jul 2020 | A1 |
20200222201 | Mirda et al. | Jul 2020 | A1 |
20200229940 | Bishop | Jul 2020 | A1 |
20200229945 | Levieux | Jul 2020 | A1 |
20200237526 | Wilson et al. | Jul 2020 | A1 |
20200246160 | Zappacosta et al. | Aug 2020 | A1 |
20200261243 | Unger et al. | Aug 2020 | A1 |
20200268523 | Barthold et al. | Aug 2020 | A1 |
20200276019 | Shetty et al. | Sep 2020 | A1 |
20200281727 | Dang et al. | Sep 2020 | A1 |
20200297494 | Hunt et al. | Sep 2020 | A1 |
20200297505 | McLaughlin | Sep 2020 | A1 |
20200315812 | Davis et al. | Oct 2020 | A1 |
20200323645 | Northcutt et al. | Oct 2020 | A1 |
20200337851 | Stampfli et al. | Oct 2020 | A1 |
20200337855 | Stauffer et al. | Oct 2020 | A1 |
20200337856 | Moore et al. | Oct 2020 | A1 |
20200345506 | Ryan et al. | Nov 2020 | A1 |
20200352735 | Afzal | Nov 2020 | A1 |
20200375757 | Sack | Dec 2020 | A1 |
20200375758 | Northcutt et al. | Dec 2020 | A1 |
20200376174 | Melkent et al. | Dec 2020 | A1 |
20210046211 | Deisinger et al. | Feb 2021 | A1 |
20210069383 | Yamaguchi et al. | Mar 2021 | A1 |
Number | Date | Country |
---|---|---|
3064175 | Sep 2016 | EP |
3494931 | Jun 2019 | EP |
3517078 | Jul 2019 | EP |
3603580 | Feb 2020 | EP |
4313005 | Aug 2009 | JP |
5328051 | Oct 2013 | JP |
5455020 | Mar 2014 | JP |
5684177 | Mar 2015 | JP |
2019034071 | Mar 2019 | JP |
2019041886 | Mar 2019 | JP |
2019180797 | Oct 2019 | JP |
2019201688 | Nov 2019 | JP |
6700135 | May 2020 | JP |
2021016498 | Feb 2021 | JP |
2009-051779 | Apr 2009 | WO |
2010-097632 | Sep 2010 | WO |
2011-159587 | Dec 2011 | WO |
2013-019543 | Feb 2013 | WO |
2014168631 | Oct 2014 | WO |
Entry |
---|
International Search Report and Written Opinion for PCT application PCT/US2016/029865 dated Aug. 19, 2016. |
Office Action dated May 5, 2017 in U.S. Appl. No. 15/141,655. |
U.S. Appl. No. 15/334,022, filed Oct. 25, 2016. |
International Search Report and Written Opinion dated May 29, 2018 for International Application No. PCT/US2018/22024. |
Number | Date | Country | |
---|---|---|---|
20200229940 A1 | Jul 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15457470 | Mar 2017 | US |
Child | 16725790 | US |